Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection shows promise for relieving debilitating skin itch

NCT ID NCT04202679

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether dupilumab, an injectable medication, could reduce severe itch and improve skin lesions in adults with prurigo nodularis, a chronic skin condition. Participants, whose symptoms were not controlled by standard prescription creams, received either dupilumab or a placebo for 24 weeks. The main goal was to see if the drug could significantly reduce the intensity of their worst itch.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEURODERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number :1240001

    Toronto, Ontario, M5A 3R6, Canada

  • Investigational Site Number :1240002

    Calgary, Alberta, T2G 1B1, Canada

  • Investigational Site Number :1240006

    Surrey, British Columbia, V3R 6A7, Canada

  • Investigational Site Number :1240007

    Markham, Ontario, L3P 1X3, Canada

  • Investigational Site Number :1240008

    Newmarket, Ontario, L3Y 5G8, Canada

  • Investigational Site Number :1240009

    Saskatoon, Saskatchewan, S7K 0H6, Canada

  • Investigational Site Number :1520001

    Santiago, Reg Metropolitana de Santiago, 7640881, Chile

  • Investigational Site Number :1520002

    Santiago, Chile

  • Investigational Site Number :1520003

    Santiago, Reg Metropolitana de Santiago, 7580206, Chile

  • Investigational Site Number :1520004

    Santiago, Reg Metropolitana de Santiago, 80004005, Chile

  • Investigational Site Number :1520005

    Valdivia, Los Ríos Region, 5110683, Chile

  • Investigational Site Number :1520006

    Osorno, Reg Metropolitana de Santiago, 5311523, Chile

  • Investigational Site Number :1580001

    Taipei, 10002, Taiwan

  • Investigational Site Number :1580002

    Taipei, 10449, Taiwan

  • Investigational Site Number :1580005

    Hsinchu, 30059, Taiwan

  • Investigational Site Number :1580006

    Kaohsiung City, 833, Taiwan

  • Investigational Site Number :1580008

    Taichung, Taiwan

  • Investigational Site Number :2500001

    Brest, 29200, France

  • Investigational Site Number :2500002

    Lille, 59037, France

  • Investigational Site Number :2500003

    Toulouse, 31059, France

  • Investigational Site Number :2500004

    Paris, 75010, France

  • Investigational Site Number :2500005

    Reims, 51100, France

  • Investigational Site Number :2500006

    Lyon, 69003, France

  • Investigational Site Number :2500007

    Bordeaux, 33075, France

  • Investigational Site Number :2500008

    Le Mans, 72037, France

  • Investigational Site Number :3480002

    Orosháza, 5900, Hungary

  • Investigational Site Number :3480003

    Szeged, 6720, Hungary

  • Investigational Site Number :3480004

    Debrecen, 4032, Hungary

  • Investigational Site Number :3480005

    Pécs, 7632, Hungary

  • Investigational Site Number :3800001

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number :3800002

    Milan, 20122, Italy

  • Investigational Site Number :3800003

    Catanzaro, 88100, Italy

  • Investigational Site Number :3800004

    Ancona, 60032, Italy

  • Investigational Site Number :4100001

    Seoul, Seoul-teukbyeolsi, 06973, South Korea

  • Investigational Site Number :4100002

    Busan, Busan, 49241, South Korea

  • Investigational Site Number :4100003

    Bucheon-si, Gyeonggi-do, 14584, South Korea

  • Investigational Site Number :4100005

    Seoul, Seoul-teukbyeolsi, 03722, South Korea

  • Investigational Site Number :4100006

    Seoul, Seoul-teukbyeolsi, 07441, South Korea

  • Investigational Site Number :4100007

    Incheon, Incheon-gwangyeoksi, 21431, South Korea

  • Investigational Site Number :6200001

    Coimbra, 3000-075, Portugal

  • Investigational Site Number :6200002

    Lisbon, 1998-018, Portugal

  • Investigational Site Number :6200003

    Porto, 4099-001, Portugal

  • Investigational Site Number :7240001

    Pontevedra, Galicia [Galicia], 36071, Spain

  • Investigational Site Number :7240002

    Zaragoza, 50009, Spain

  • Investigational Site Number :7240003

    Valencia, 46026, Spain

  • Investigational Site Number :7240004

    Córdoba, 14004, Spain

  • Investigational Site Number :7240007

    Madrid, 28034, Spain

  • Investigational Site Number :7240008

    Santullano, Principality of Asturias, 33619, Spain

  • Investigational Site Number :7240009

    Badalona, Barcelona [Barcelona], 08916, Spain

  • Investigational Site Number :8260001

    Redhill, Surrey, RH1 5RH, United Kingdom

  • Investigational Site Number :8400001

    Sugar Land, Texas, 77479, United States

  • Investigational Site Number :8400002

    Plainfield, Indiana, 46168, United States

  • Investigational Site Number :8400003

    Baltimore, Maryland, 21205, United States

  • Investigational Site Number :8400005

    Pembroke Pines, Florida, 33028, United States

  • Investigational Site Number :8400006

    East Windsor, New Jersey, 08520, United States

  • Investigational Site Number :8400008

    Sacramento, California, 95816, United States

  • Investigational Site Number :8400054

    Fort Smith, Arkansas, 72916, United States

Conditions

Explore the condition pages connected to this study.

NEURODERMATITIS